Submission & ApprovalLast reviewed May 2026

Market Exclusivity(Exclusivity)

FDA-granted periods during which generic or biosimilar competition is delayed for certain approved drugs and biologics.

Usage Examples

The NDA received 5 years of NCE exclusivity from first approval.
Orphan Drug Exclusivity blocked competing orphan product approval for the same indication for 7 years.
Pediatric exclusivity extended NCE exclusivity by an additional 6 months.

What is Exclusivity?

Market exclusivity is FDA's regulatory mechanism for delaying generic drug (ANDA) or biosimilar (351(k)) approval for specified periods after a reference product approval. Exclusivity is distinct from patent protection: patents are granted by USPTO and protect the invention; exclusivity is granted by FDA and delays a specific type of competing application.

For small molecule drugs, key exclusivity types include 5-year New Chemical Entity (NCE) exclusivity for first approval of a new active moiety (blocks ANDA and 505(b)(2) submissions for 5 years, or 4 years if Paragraph IV certification); 3-year exclusivity for NDAs or supplements containing new clinical investigations essential to approval; 7-year Orphan Drug Exclusivity for designated orphan products; and 6-month Pediatric Exclusivity extending other exclusivities when qualifying pediatric studies are completed.

For biologics under the BPCIA, 12 years of Reference Product Exclusivity blocks biosimilar approval, with the first 4 years preventing biosimilar submissions entirely. Exclusivity runs from the first BLA approval date. Patent certifications in the Orange Book and Purple Book track both patent and exclusivity status, informing generic and biosimilar launch timing.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDCA SECTION 505, PHSA SECTION 351, HATCH WAXMAN ACT.

FDAICHEMA

When This Matters

The NDA received 5 years of NCE exclusivity from first approval.
Orphan Drug Exclusivity blocked competing orphan product approval for the same indication for 7 years.
Pediatric exclusivity extended NCE exclusivity by an additional 6 months.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

FDCA SECTION 505PHSA SECTION 351HATCH WAXMAN ACTBPCIA

Frequently Asked Questions

Patents are granted by USPTO for inventions and last 20 years from filing (minus prosecution time). Exclusivity is granted by FDA and delays specific types of competing applications for specified periods. Patents and exclusivity can overlap or extend different periods; exclusivity is FDA-specific and independent of patent protection.

NCE exclusivity blocks ANDAs and 505(b)(2) applications for the same active moiety for 5 years (or 4 years if Paragraph IV certification, with the 30-month stay of approval potentially extending further). It does not block a competitor's own 505(b)(1) NDA for the same indication or a different active moiety.

FDA issues a Written Request for pediatric studies. If the sponsor completes the requested studies and submits the results, and the studies meet FDA's criteria, the sponsor receives a 6-month extension of existing exclusivities and patent terms on all strengths and dosage forms of the drug. Pediatric exclusivity is attached to the drug, not a specific study result.